β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
A Randomized Clinical Trial Exploring β-alanine as an Adjunct to First-line Immunotherapy in Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
158 participants
Dec 24, 2025
INTERVENTIONAL
Conditions
Summary
This study is a prospective, randomized controlled study on nutritional support and metabolic regulation. It assesses the safety, compliance, and improvement of metabolic/physical-related indicators when using β-alanine within the specified dose range as dietary supplementation, in addition to the standard first-line treatment. The anti-tumor efficacy (ORR, PFS, OS) is the exploratory endpoint.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®)+β- alanine
Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®)
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07317414